ArticleMikrochimica acta2026
Non-invasive urine-based detection of PSMA-positive exosomes using a dual-aptamer electrochemical aptasensor for prostate cancer diagnosis.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Electrochemical liquid biopsy across cancer care pathway.The journal of liquid biopsy · 2026Review
- Urine-based PSMA detection for noninvasive prostate cancer diagnosis: recent advances, translational challenges, and future perspectives.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel electrochemical aptamer-based biosensor is reported for label-free detection of prostate-specific membrane antigen (PSMA)-positive exosomes in human urine. The platform integrates magnetic nanoparticles functionalized with CD63-specific aptamers (mMNPs) for efficient exosome capture, and screen-printed electrodes (SPEs) modified with carbon nanofibers (CNFs) and immobilized PSMA-specific aptamers for targeted detection. Differential pulse voltammetry (DPV), electrochemical impedance spectroscopy (EIS) and cyclic voltammetry (CV) confirmed the successful stepwise modification of the electrode surface and target recognition. The biosensor demonstrated excellent analytical performance for PSMA protein detection in exosome isolates, with a detection limit of 3 pg/mL and a linear response from 10 to 1400 pg/mL as quantified by ELISA. Specificity was confirmed using exosomes from PSMA-negative PC3 cell cultures and benign samples. Reproducibility and stability tests were conducted using exosomes isolated from the LNCaP cell culture, which confirmed operational robustness. Clinical urine testing showed high agreement with PSMA ELISA results, and urinary creatinine normalization improved data reliability across samples. This dual-aptamer biosensor offers a highly specific, reproducible, and non-invasive strategy for early prostate cancer diagnosis, with strong potential for point-of-care and clinical translation.
Indexed as
Identifiers
41505006What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.